cyrilzakka/clinical-trials huggingface dataset:
Effectiveness Taif University P. O. Box 11099 Taif 21944 Effectiveness of Dry Needling in Management of Myofacial Trigger Point

myofascial pain syndrome is considered to be a chronic condition due to sensitive pressure points within the muscle recognized as trigger points

Generally the aim of this study will be :

* To investigate the effectiveness of dry needling on trigger point in trapezius muscle
* Evaluate the pain level before and after the applications of dry needling on trigger points
* compare between the effects of dry needling and physical therapy exercise program


Eligibility Criteria:
Inclusion Criteria:

* Clinically active trigger point and expression of symptoms of neck pain in trapezius which had lasted for at least 3 months.
* Having a pain level higher than 4 and lower than 8 on Visual Analogue Scale ( VAS )
* Did not receive any other form of neck treatment during the previous month.

Exclusion Criteria:

* Presence of cardiopulmonary disease , the application process requires the subject to be in prone position to expose the area of treatment, this position is un-preferable for cardiopulmonary patients
* History of neck surgery
* Trigger point treatment in the last 30 days
* Any contraindications for dry needling such as local infection, skin disease ,severe postural disorder , tumor , rheumatoid arthritis, cervical spine stenosis and bilateral upper extremity symptoms
* pregnancy
REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion

The aim of the study was to establish a clinical and advanced imaging database of acute ischemic stroke patients treated with mechanical thrombectomy due to large vessel occlusion of anterior circulation within 24 hours from stroke onset in China, and to investigate the predictors and potential mechanisms of futile recanalization after mechanical thrombectomy.

The time-window of mechanical thrombectomy for ischemic stroke has extended from 4.5 hours to 24 hours based on the results of the DAWN and DEFUSE 3 trials. However, evidence on the effectiveness and safety of mechanical thrombectomy within 24 hours in the real-world is insufficient.

This is a multi-center, prospective, registry cohort study that acute ischemic stroke patients treated with mechanical thrombectomy due to large vessel occlusion of anterior circulation within 24 hours from stroke onset in China. A retrospective dataset was also build in these stroke centers for analysis. A total of 1600 patients with advanced imaging data were anticipated to be enrolled.

Eligibility Criteria:
Inclusion Criteria:

* Older than 18 years;
* Perfusion imaging completed including CTA+CTP or MRA+PWI+DWI before thrombectomy
* Large vessel occlusion of cerebral anterior circulation (ICA, MCA-M1 or MCA-M2) confirmed by CTA or MRA, planned to receive or received stenting or aspiration thrombectomy
* Time intervals ≤ 24 hours from stroke onset to groin puncture.(fulfilled the inclusion of DAWN or DEFUSE 3 trial if the time intervals from stroke onset to groin puncture was ≥6 hours)
* mRS score ≤2 before admission
* Informed consent obtained for longitudinal enrolled patients, waived of consent for retrospectively included cases

Exclusion Criteria:

* Had a history of infective disease, immunity disease, radiotherapy at head or neck, carotid dissection or other carotid disease.
* Unable to receive CT or MR scan due to heart failure, cardiac pacemaker, metal implants or claustrophobia, etc.
* Unable to be injected with contrast agent due to allergy, renal dysfunction, etc.
* Unlikely to adhere to the study protocol or follow-up ( life expectancy ≤ 3 months)
* Already participated in other drug trials
A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Primary objective of this trial will be to evaluate the safety and efficacy of intravitreal injections of Macugen (pegaptanib sodium) when given at least 7-14 days prior to vitrectomy in subjects with tractional retinal detachment (with or withoutmacular involvement) secondary to proliferative diabetic retinopathy.

Secondary objective is to evaluate regression of neovascularization and progression of macular traction utilizing OCT and fundus photographs.


Eligibility Criteria:
Inclusion Criteria:

* Subjects of either gender aged 75 years or below diagnosed with tractional retinal detachment secondary to proliferative diabetic retinopathy.

Exclusion Criteria:

* Subjects with vitreous hemorrhage obscuring the posterior pole will be excluded.
Blood Donor CVD 9000

This is an open-label, non-randomized study. Volunteers will be vaccinated with the oral cholera vaccine, Vaxchora. Vaxchora has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.


Eligibility Criteria:
Inclusion Criteria:

* 1. Age 18 years to 64 years at the time of enrollment
* 2. Good general health as determined by a screening evaluation within 28 days before blood donation or vaccination
* 3. Provides written informed consent prior to initiation of any study procedures

Exclusion Criteria:

* 1. History of any of the following medical conditions:

  * Diabetes
  * Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical carcinoma in situ)
  * Heart disease (e.g., hospitalization for a heart attack, coronary artery bypass graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease, such as dyspnea, angina, or orthopnea)
  * Recurrent infections (e.g., more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis)
  * Current drug or alcohol abuse
  * Active ulcer disease or ongoing intestinal condition
  * Treatment for anemia in last 6 months
  * Treatment with anti-malarial drugs within ten days prior to study vaccination
  * Treatment with antibiotics within 14 days prior to study vaccination
  * Immunodeficiency or immunosuppression from illness or treatment
* 2. Close contact within 7 days following study vaccination with a person who has an immunodeficiency or immunosuppression from illness or treatment
* 3. History of cholera infection or cholera vaccination
* 4. Any of the following complete blood count (CBC) abnormalities during screening:

  * white blood cells (WBC) \<0.81 x lower limit of normal (LLN) or \> 1.09 x upper limit of normal (ULN)
  * Hemoglobin \<0.91 x LLN or \>1.18 x ULN (women) or \<0.92 x LLN or \>1.18 x ULN (men)
  * Platelet count \<0.8 x LLN or \> 1.2 x ULN
* 5. Any of the following laboratory abnormalities during screening:

  * serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) \>1.5 times normal
  * Positive serology for HIV antibody
* 6. Poor peripheral venous access for blood donation
* 7. Other condition that the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or interfere with the scientific integrity of study
* 8. Positive urine pregnancy test (HCG) on the day of vaccination
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed as Chronic Myelogenous Leukemia in Chronic Phase
* Previously untreated with Interferon-alpha
* Performance status is normal or capable of only limited self-care

Exclusion Criteria:

* Patients who are pregnant or possibly pregnant
* Significant hepatic diseases
* Chronic Myelogenous Leukemia in advanced phase

Other protocol-defined inclusion/exclusion criteria may apply.
Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Known Devices

The purpose of this prospective single center study is to investigate if a developed algorithm is more accurate than the Broselow Tape (BT). For this study 500 patients are required to collect anonymized data (length, weight, age, anaesthesia material used during anaesthesia) for achieving a power of 80% during statistical analysis. The main hypothesis ist that the algorithm has a better accuracy than the BT.

This prospective single center study is performed at the university children's hospital zurich. Patients planned for surgery in general anaesthesia with intubation, aged 0 to 16 years and with a body length suitable for the emergency tapes can be included in this study. Patient and parental information is performed during the pre-anaesthetic visit.

After written consent the patient will be included. Patient ́s length and weight will be measures earliest one day before data collection. Data collection during anaesthesia has no influence on the daily anaesthesia routine and has no impact on patient safety and anaesthesia. Patient's data is made anonymous for further inspection. Data is documented in Microsoft Excel and statistical analysis calculated with SPSS.

500 patients are needed for a power of 80%. Primary outcome parameter is length- based weight estimation, secondary outcome parameters are length-based age estimation and the correctness of recommended anaesthesia material (endotracheal tube, laryngeal mask, oropharyngeal mask and face mask). Both tools (algorithm and BT) will be compared with each other regarding primary and secondary outcome parameters.

Eligibility Criteria:
Inclusion Criteria:

* body length suitable with the investigated emergency tapes
* all patients aged 0 -16 years
* receiving general anaesthesia with intubation or laryngeal mask

Exclusion Criteria:

* Already included in this study once
* missing patient or parental consent
Randomised Comparison of 2 Cold Snare Polypectomy Techniques

Different modalities are employed to remove small colonic polyps which potentially harbour a cancer risk. But, they can all vary in their completeness of removal, safety and the histological quality and the gold standard technique has yet to be defined. A novel suction pseudopolyp technique has been described by Patullo et al and in their prospective study, 126 polyps measuring less than 10mm flat or sessile were removed by this method with 100% complete endoscopic resection and without any immediate or delayed complications. The aim of the investigators study is to compare this technique with the standard cold snare technique. Patients attending for a routine colonoscopy and found to have polyps measuring 37mm in size will be eligible and they will be randomised to the polypectomy technique. Patient demographics and polyp characteristics will be recorded. The primary outcome measured will be the macroscopic resection rate. The secondary outcome measures are abdominal pain, tenderness, bleeding and fever.


Eligibility Criteria:
Inclusion Criteria:

* All patients with small polyps 3-7 mm in size, flat or sessile found during colonoscopy

Exclusion Criteria:

* Patients are less than 18 years old
* Pregnant
* Inadequate bowel preparation
* On anticoagulants or clopidogrel
Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities

AIM: Improve adherence to physical activity in people with Intellectual disabilities with a Smartphone Application DESIGN: Randomized controlled trial SUBJECTS OF THE STUDY: People with intellectual disabilities in Occupational Center ( ASPROMANIS) INTERVENTION: DATA ANALYSIS: descriptive statistics, measuring central tendency and dispersion of the variables study. Inferential statistics will be made between intervention of key variables and outcome


Eligibility Criteria:
Inclusion Criteria:

* Participants were can write and read to ask scales
* Participant were able to use an Smartphone

Exclusion Criteria:

* Physical illness that prevent physical activity
Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

Photodynamic therapy is an effective treatment for actinic keratoses. In the United States topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment, and it has traditionally been activated with the use of an in-office artificial light source. This clinical trial seeks to measure the safety and efficacy of using natural sunlight to activate the ALA.

* Initial Visit:

  * study inclusion criteria reviewed
  * consent forms reviewed
  * creation of facial map for actinic keratoses
  * face cleansed with chlorhexidine soap
  * light curettage of precancerous skin lesions
  * application of topical aminolevulinic acid (ALA)
  * application of sunscreen
  * patient then spends 2 hours outdoors in a shaded area
  * after treatment the patient is to remain indoors for 48 hours
* 3 month follow up visit

  - facial map of actinic keratoses used to document treatment response
* 6 month follow up visit

  * facial map of actinic keratoses used to document treatment response

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of \>10 actinic keratoses on head and neck
* Age ≥ 18 years (Because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients \<18 years of age, children are excluded from this study)
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Patients currently undergoing anti-neoplastic therapy including but not limited to the following:

  * Topical imiquimod
  * Topical 5-fluorouracil
  * Topical ingenol mebutate
  * Topical diclofenac
  * Topical retinoids
  * Oral acitretin
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid
* Patients with a known photosensitivity disorder including but not limited to porphyria, lupus, polymorphous light eruption, or immunobullous disease.
* Patients taking known photosensitizing medications including but not limited to griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines.
* pregnancy
Glucocorticoids and Pulmonary Hypertension

Pediatric idiopathic pulmonary hypertension has significant morbidity and mortality. An ever expanding body of knowledge indicates the important contribution of inflammation to pathogenesis and successful treatment with glucocorticoids. Over the last several years the investigators have utilized steroids in patients with severe pulmonary hypertension as part of a treatment regimen. These basic science studies possibly identifies a biochemical etiology for the development of disease and may also be impacted by the administration of steroids. Additionally, there is a commercially available assay which tests for all of the above molecules.


Eligibility Criteria:
Inclusion Criteria:

* premature, BPD, \>36 wga
* pulmonary hypertension evidence by echocardiogram

Exclusion Criteria:

* poor ventilation/oxygenation
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.


Eligibility Criteria:
Inclusion Criteria:

* woman, age \> 18 years old
* diagnosed with HER2 +Metastatic Breast Cancer
* pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05
* available medical history

Exclusion Criteria:

* medical history was incomplete
Comparison of Double-kissing Crush and Double-kissing Culotte Stenting

True bifurcation lesions (TBLs) are not rare clinical conditions and may be associated with adverse cardiovascular outcomes due to their complex anatomy and the variety of interventional therapy. Although the provisional stenting is still effective in suitable lesions, double stent techniques can be required in selected patients. In previous studies, double kissing crush (DK-crush) stenting was revealed as superior to provisional stenting in TBL of left main coronary artery. Additionally, in recent studies, double kissing approach facilitates and highlights double kissing culotte (DK-culotte) stenting with lower stent malapposition compared to DK-crush stenting. However, to the best of our knowledge, there is no study about comparing DK-crush and DK-culotte stenting in TBLs. Our aim in this study is to compare DK-crush and DK-culotte stenting in patients with TBL.


Eligibility Criteria:
Inclusion Criteria:

* Patients with de novo true bifurcation lesion (Medina classification 1,1,1 or 0,1,1 or 1,0,1)
* The main vessel diameter is least 2.5 mm and the side branch diameter is at least 2.25 mm

Exclusion Criteria:

* Patients presenting with ST segment elevation myocardial infarction, cardiogenic shock and Killip class III-IV heart failure
* Patients with a history of coronary artery bypass grafting surgery
* Patients with a chronic total occlusion in the bifurcation area
* Lesions with severe calcification that needs additional intervention such as atherectomy
* Patients who are not suitable to use long term dual antiplatelet therapy and patients not participating in clinical follow-up
* Patients with hematological disorders, malignancy, end stage renal (GFR\<30 ml/min) and hepatic failure
* Patients with active bleeding
* Pregnant women
* Patients with life-expectancy \< 1 year
Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels

The aim of this study is to investigate the effects of non invasive brain stimulation - NIBS - techniques (Electroconvulsivotherapy - ECT, transcranial Direct Current Stimulation - tDCS, repetitive transcranial magnetic stimulation - rTMS) on serum Brain Derived Neurotrophic factor (BDNF) levels in patients with depression and schizophrenia. Four blood samples will be collected in each participants, one before the NIBS sessions, and 3 after the completion of NIBS protocols: one immediately after the end of the NIBS sessions, a second one week after and a last one month after. Two blood samples separated by one month will also be collected in a a group of healthy volunteers.

The hypothesis is that NIBS will modulate BDNF levels and that the modification in serum BDNF levels will be correlated with clinical improvements in the sample of patients.

Eligibility Criteria:
Inclusion Criteria:

* in the depression group: DSM IV criteria of MDD; HDRS17\> 22; stage 2 of resistance; received rTMS or ECT
* in the schizophrenia group DSM IV criteria of schizophrenia; pharmaco-resistance of symptoms (either negative symptoms or auditory verbal hallucination); received rTMS or tDCS
* in the healthy volunteers group : to not have axis I of DSM IV diagnosis; no siblings with axis I DSM IV diagnosis

Exclusion Criteria:

* less than 18 years old
* pregnancy
* received benzodiazepine

In the depression and schizophrenia group:

* bipolar disorder
* other axis I of DSM IV diagnosis (excluding for Tobacco use disorder)
Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

The primary purpose of this first-in-human, early feasibility study is to assess safety and feasibility of the Low-Irradiance Monochromatic Biostimulation (LIMB) System as a phototherapeutic intervention for the management of acute burn wounds. The prototype LIMB device will be evaluated for the occurrence of adverse events (treatment-related or otherwise) of the LIMB System, a portable, wearable, light-emitting system developed by Rogers Sciences, Inc. (RSI). The device will be administered in the small feasibility pilot to confirm design, usability and operating specifications that will inform procedures and endpoints of a subsequent large, multicenter clinical trial.


Eligibility Criteria:
Inclusion Criteria:

* Patients receiving care at Shriners Hospitals for Children-Boston for a skin tissue injury.
* Patients who have at least one wound with exposed area sufficient, in the Investigator's opinion, to receive LIMB therapy.
* Willing and able to adhere to daily LIMB therapy protocol.

Exclusion Criteria:

* Patients deemed not medically stable by the treating Investigator.
* Patients with clinical signs and symptoms of systemic infection at baseline.
* Patients with burn wounds limited to their head and genitalia.
* Patients who, in the opinion of the Investigator, will not require daily dressing changes.
* Patients receiving photosensitizing agents that result in cutaneous phototoxicity prior to enrollment. Patients who have received one or more of the following photosensitizers cannot be enrolled into the study: photofrin, amiodarone, chloropromazine, fluoroquinolone antibiotics, thiazide diuretics, quinine, demethylchlortetracycline, psoralens, nalidixic acid, tetracycline, naproxen.
* Patients currently enrolled or participating in another investigational device, drug or biological trial within 30 days of the Screening Visit.
* Patients currently receiving any bandages or devices containing silver compounds.
* Patients on a ventilator, who have fluid resuscitation or are in any terminal condition.
The Value of HPV Testing for Cervical Cancer Screening in Women Living With HIV (PAPILLO-VIH)

The main objective of this study is to evaluate the interest of a screening strategy based on the HPV test in patients living with HIV, compared to the cell smear alone in the same population.

The Secondary objective of this study is to verify if the use of HPV testing could allow for a longer follow-up of these patients in case of negativity, and thus allow for a standardization of clinicians' practices.

Since 2019, a new screening strategy has been implemented and is based on high-risk, HPV tests, which, when negative, allow for spaced monitoring in the general population after age 30 (every 5 years instead of every 3 years.)

These tests therefore allow for earlier detection of patients at risk but also for longer follow-up when they are negative.

To our knowledge, there is currently no evaluation of HPV testing as part of routine screening in patients living with HIV.

The recommendations for this population are based on the use of the cervico-vaginal smear with cytological analysis. The smear should be taken every year and surveillance may be repeated every 3 years. If there are 3 consecutive smears without abnormalities and a controlled viral load with CD4 counts \> 500 mm3. In practice, many patients do not meet these criteria and must, therefore, undergo annual screening; the increase in the number of smears also leads to an increase in the number of second-line examinations such as colposcopy.

Since there is no recommendation for HPV testing in this population, the use of dual detection (cytology and HPV testing) is left to the discretion of the clinician.

By mutual agreement with the clinicians of the maternity department of the Saint-Denis Hospital (CHSD), this double detection was introduced in 2021, using the same sample (single swab for both analyses: cytology and HPV test).

Therefore, it seems interesting to verify the possibility of a screening strategy based on HPV testing in patients living with HIV, by correlating the results of HPV testing and cell smears in the population of patients living with HIV.

Eligibility Criteria:
Inclusion Criteria:

* Women living with HIV
* Age 25-65 years
* Managed in the CHSD maternity ward: consultation or hospitalization
* Having signed a consent form

Exclusion Criteria:

* Age ≤ 24 years, or ≥ 66 years
* Women who are not HIV positive
* Patients under legal protection (guardianship, curatorship)
* Patients deprived of liberty
* Patients not affiliated to a social security system
* Refusal to participate in the research